Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 10, 2025
Deals
Sun takes shine to Checkpoint in $355M buyout: Deals Report
Plus: Jazz acquires Chimerix for 72% premium, and J&J does not exercise HexaBody Genmab option, Myokardia ends partnership with Fulcrum
BioCentury | Jul 8, 2024
Deals
Via $3.2B Morphic deal, Lilly gets oral integrin to compete in Entyvio’s class
Small molecule program, now in Phase II, could challenge injectable blockbuster; joins IBD drug Omvoh in pharma’s immunology arsenal
BioCentury | May 16, 2024
Finance
Venture Report: Blackstone eyes pipeline-in-a-product via Uniquity launch
Plus: New funds for Sands and NewVale, and series C rounds for Lycia and Ajax
BioCentury | Apr 23, 2024
Deals
Incyte’s hopes for mast cell program spur $750M Escient takeout
Deal gives Incyte clinical molecules for inflammatory, dermatological disorders
BioCentury | Nov 11, 2023
Data Byte
After a second look, EMA’s CHMP recommends Mirati’s KRAS inhibitor
CHMP’s November opinions include four new medicines and an expansion of Mounjaro’s label to include obesity
BioCentury | Oct 18, 2023
Data Byte
FDA’s NME approvals in September
Agency approved two new cancer and one new neuro drug; plus Amicus’ Pompe therapy among pair of approvals for rare metabolic disorders
BioCentury | Sep 15, 2023
Regulation
Sept. 15 Quick Takes: FDA approves GSK’s momelotinib, gained in $1.9B Sierra deal
Plus: Oral arguments in IRA suit consistent with briefs, and updates from Iovance and MAPS
BioCentury | Sep 6, 2023
Data Byte
11 PDUFA dates on FDA’s agenda in September
Decisions due this month include BioLineRx’s Aphexda, Roche’s subcutaneous Tecentriq and GSK’s momelotinib
BioCentury | Jun 16, 2023
Regulation
June 16 Quick Takes: Roche wins bispecific approval
Plus: FDA extends momelotinib’s review, and Neuvivo raises cash
Items per page:
1 - 10 of 466